Home    eJManager.com Add Your Journal   |    Follow on Twitter   |    Subscribe to List

Directory for Medical Articles
 

Open Access

Editorial

RMJ. 2004; 29(1): 1-2


What to do with the fatty liver

Nasir Khokhar.

Abstract
Ever since the first description, quarter of century ago (1), nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a condition that may progress to end stage liver disease. There are many risk factors for the development of fatty liver (2). However, diabetes mellitus, obesity and hyperlipidemia have been the most commonest seen (2,3). NAFLD is prevalent worldwide with varying degrees in various countries and has ranged from 10-24 % in general population and nearly 75% in obese patient (4). It is becoming more common as obesity becomes a major medical problem (5). NAFLD is found in both sexes but women have been noted to be victim of this condition more often (2). The natural history is not as benign as once was thought to be, as more and more cases of cryptogenic cirrhosis have been attributed to fatty liver (6) and end stage liver with increased mortality (7) and even liver cancer has been associated with this (8).

Key words: NAFlD, NASH, Fatty liver, hepatic steatosis



Share this Article




ScopeMed Home
Follow ScopeMed on Twitter
Article Tools
Job Opportunities/Service Offers
eJManager OJMS
eJPort Journal Hosting
About ScopeMed
Terms & Conditions
Privacy Policy
Suggest a Journal
Publisher Login
Contact Us

The articles in Scopemed are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Service of eJManager LLC Publishing for Scientific Publications. Copyright © ScopeMedź Information Services.
Scopemed Buttons